Part 6/7:
Switching gears, Deets highlighted CVS and Nestlé as compelling investments going forward. He underscored CVS's strong foothold in healthcare, particularly after merging with Aetna, and predicted substantial earnings growth in the healthcare sector for the upcoming year. He framed CVS as an attractive opportunity, given its low price-to-earnings valuation and generous dividend yield.
Looking Ahead to 2025
As they wrapped up the conversation, Fitzgerald expressed optimism, questioning the relevance of factors such as Federal Reserve actions, bond yields, and potential deflationary pressures on their investment strategies. He emphasized the need to focus on companies and sectors that are likely to thrive in changing markets and not get bogged down by short-term fluctuations.